Mary Wilson
Well-known member
Early Release / July 6, 2021 / 70
Julia W. Gargano, PhD[SUP]1,[/SUP]*; Megan Wallace, DrPH[SUP]1,[/SUP]*; Stephen C. Hadler, MD[SUP]1[/SUP]; Gayle Langley, MD[SUP]1[/SUP]; John R. Su, MD, PhD[SUP]1[/SUP]; Matthew E. Oster, MD[SUP]1[/SUP]; Karen R. Broder, MD[SUP]1[/SUP]; Julianne Gee, MPH[SUP]1[/SUP]; Eric Weintraub, MPH[SUP]1[/SUP]; Tom Shimabukuro, MD[SUP]1[/SUP]; Heather M. Scobie, PhD[SUP]1[/SUP]; Danielle Moulia, MPH[SUP]1[/SUP]; Lauri E. Markowitz, MD[SUP]1[/SUP]; Melinda Wharton, MD[SUP]1[/SUP]; Veronica V. McNally, JD[SUP]2[/SUP]; José R. Romero, MD[SUP]3[/SUP]; H. Keipp Talbot, MD[SUP]4[/SUP]; Grace M. Lee, MD[SUP]5[/SUP]; Matthew F. Daley, MD[SUP]6[/SUP]; Sara E. Oliver, MD[SUP]1[/SUP]
Summary
What is already known about this topic?
An elevated risk for myocarditis among mRNA COVID-19 vaccinees has been observed, particularly in males aged 12–29 years.
What is added by this report?
On June 23, 2021, the Advisory Committee on Immunization Practices concluded that the benefits of COVID-19 vaccination to individual persons and at the population level clearly outweighed the risks of myocarditis after vaccination.
What are the implications for public health practice?
Continued use of mRNA COVID-19 vaccines in all recommended age groups will prevent morbidity and mortality from COVID-19 that far exceed the number of cases of myocarditis expected. Information regarding the risk for myocarditis with mRNA COVID-19 vaccines should be disseminated to providers to share with vaccine recipients.
https://www.cdc.gov/mmwr/volumes/70/wr/mm7027e2.htm?s_cid=mm7027e2_w
Julia W. Gargano, PhD[SUP]1,[/SUP]*; Megan Wallace, DrPH[SUP]1,[/SUP]*; Stephen C. Hadler, MD[SUP]1[/SUP]; Gayle Langley, MD[SUP]1[/SUP]; John R. Su, MD, PhD[SUP]1[/SUP]; Matthew E. Oster, MD[SUP]1[/SUP]; Karen R. Broder, MD[SUP]1[/SUP]; Julianne Gee, MPH[SUP]1[/SUP]; Eric Weintraub, MPH[SUP]1[/SUP]; Tom Shimabukuro, MD[SUP]1[/SUP]; Heather M. Scobie, PhD[SUP]1[/SUP]; Danielle Moulia, MPH[SUP]1[/SUP]; Lauri E. Markowitz, MD[SUP]1[/SUP]; Melinda Wharton, MD[SUP]1[/SUP]; Veronica V. McNally, JD[SUP]2[/SUP]; José R. Romero, MD[SUP]3[/SUP]; H. Keipp Talbot, MD[SUP]4[/SUP]; Grace M. Lee, MD[SUP]5[/SUP]; Matthew F. Daley, MD[SUP]6[/SUP]; Sara E. Oliver, MD[SUP]1[/SUP]
Summary
What is already known about this topic?
An elevated risk for myocarditis among mRNA COVID-19 vaccinees has been observed, particularly in males aged 12–29 years.
What is added by this report?
On June 23, 2021, the Advisory Committee on Immunization Practices concluded that the benefits of COVID-19 vaccination to individual persons and at the population level clearly outweighed the risks of myocarditis after vaccination.
What are the implications for public health practice?
Continued use of mRNA COVID-19 vaccines in all recommended age groups will prevent morbidity and mortality from COVID-19 that far exceed the number of cases of myocarditis expected. Information regarding the risk for myocarditis with mRNA COVID-19 vaccines should be disseminated to providers to share with vaccine recipients.
https://www.cdc.gov/mmwr/volumes/70/wr/mm7027e2.htm?s_cid=mm7027e2_w